Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)
European Journal of Cancer · 2024-09 · 209 · 114241
DOI: 10.1016/j.ejca.2024.114241 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift European Journal of Cancer, 2024-09. Verfasst von Jennifer H Foster und 11 weiteren Autor:innen. Beteiligte Einrichtung: Texas Children's Hospital, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA. Electronic address: jhfoster@bcm.e…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Neoplasms, Pyrimidines, Cyclopentanes. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE: The objective of this study was to determine the recommended Phase 2 dose (RP2D) of pevonedistat, a first in class inhibitor of NEDD8 activating enzyme, in combination with irinotecan (IRN) and temozolomide (TMZ) in children with cancer. METHODS: This Phase 1 study used a rolling 6 design to evaluate escalating doses of pevonedistat in combination with standard doses of IRN and TMZ in pediatric patients with recurrent/refractory solid or CNS tumors. During cycle 1, pevonedistat was administered intravenously on days 1, 8, 10, and 12, with IRN (IV, 50 mg/m2) and TMZ (orally, 100 mg/m2), on days 8-12 of a 28-day cycle. In subsequent cycles, pevonedistat was administered on days 1, 3, and 5, with IRN/TMZ on days 1-5 of a 21-day cycle. RESULTS: Thirty patients enrolled; all were eligible and evaluable for toxicity. Six patients each enrolled on pevonedistat dose levels (DL) 1 (15 mg/m2), 2 (20 mg/m2), 3 (25 mg/m2) and 4 (35 mg/m2) as well as an expanded pharmacokinetic (PK) cohort at DL4. The maximum tolerated dose (MTD) was not exceeded. 2/12 (17 %) patients treated at the RP2D (35 mg/m2) experienced a cycle 1 dose limiting toxicity (DLT). IRN is unlikely to affect the pharmacokinetics of pevonedistat. Two patients had a partial response and 6 patients had prolonged stable disease (> 6 cycles). CONCLUSIONS: Pevonedistat in combination with IRN/TMZ is well tolerated in children with solid or CNS tumors. The RP2D of pevonedistat is 35 mg/m2 on days 1, 3, 5 in combination with IRN/TMZ.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Texas Children's Hospital, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA. Electronic address: jhfoster@bcm.edu.
- Mayo Clinic, Rochester, MN, USA.
- Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA.
- Texas Children's Hospital, Baylor College of Medicine, Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA.
- Department of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.
- Children's Hospital Los Angeles, Radiology, Keck USC School of Medicine, Los Angeles, CA, USA.
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
Zitieren
APA
Foster, J. H., Reid, J. M., Minard, C., Woodfield, S., Denic, K. Z., Isikwei, E., Voss, S. D., Nelson, M., Liu, X., Berg, S. L., Fox, E., & Weigel, B. J. (2024). Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). European Journal of Cancer, 209, 114241. https://doi.org/10.1016/j.ejca.2024.114241
Vancouver
Foster JH, Reid JM, Minard C, Woodfield S, Denic KZ, Isikwei E, et al. Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615). European Journal of Cancer. 2024;209:114241. doi:10.1016/j.ejca.2024.114241
BibTeX
@article{Foster2024,
author = {Foster, Jennifer H and Reid, Joel M and Minard, Charles and Woodfield, Sarah and Denic, Kristina Z and Isikwei, Emasenyie and Voss, Stephan D and Nelson, Marvin and Liu, Xiaowei and Berg, Stacey L and Fox, Elizabeth and Weigel, Brenda J},
title = {Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)},
journal = {European Journal of Cancer},
year = {2024},
volume = {209},
pages = {114241},
doi = {10.1016/j.ejca.2024.114241}
}
EUVIMED